We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
story of the week
Published in Benign Hematology

Journal Scan / Research · December 25, 2018

Ravulizumab vs Eculizumab in C5-Inhibitor–Experienced Adult Patients With PNH

Blood

 

Save Recommend
Share

Additional Info

Disclosure statements are available on the authors' profiles:

Eric Fountain MD, MA

Blood
Ravulizumab (ALXN1210) vs Eculizumab in C5-Inhibitor–Experienced Adult Patients With PNH: The 302 Study
Blood 2018 Dec 03;[EPub Ahead of Print], AG Kulasekararaj, A Hill, ST Rottinghaus, S Langemeijer, R Wells, FA Gonzalez-Fernandez, A Gaya, JW Lee, E Ojeda Gutierrez, CI Piatek, J Szer, A Risitano, S Nakao, E Bachman, L Shafner, AI Damokosh, S Ortiz, A Röth, R Peffault de Latour

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated